newsfilter
← Latest News
GlobeNewswire·

Seer Files Patent Infringement Lawsuit Against Nanomics

  • Seer Inc. filed a patent infringement lawsuit against Nanomics Biotechnology Co., Ltd. on May 13, 2026.
  • Brigham & Women's Hospital is joining the lawsuit to support Seer's legal action.
  • The suit asserts five U.S. patents (Nos. 11,435,360; 11,630,112; 12,050,222; 12,228,566; 12,590,948) protecting Seer's nanoparticle protein enrichment IP.
  • Seer holds over 250 patent applications & 84 issued patents globally, with a significant portion defending the Proteograph Product Suite.
  • On March 23, the Patent Trial and Appeal Board upheld key claims in U.S. Patent No. 11,435,360 during an Inter Partes Review.
  • Seer alleges Nanomics infringes these patents by manufacturing, using, selling, & offering to sell Proteonano kits & workstations.
  • Seer is seeking monetary damages & injunctive relief against Nanomics.
  • Seer's CEO Omid Farokhzad stated the proprietary engineered nanoparticle technology is core to the company's solutions & will be defended fully.
  • Seer's Proteograph Product Suite integrates nanoparticles, automation, consumables, & software for deep, unbiased proteomics research.
  • Seer's products are designated for research use only & are not intended for diagnostic procedures.